ClinicalTrials.gg
RecruitingNCT07188415Updated Sep 23, 2025

CMT Gait, Mobility, Balance - AOFAS Grant

An interventional study of Ankle-foot Orthoses in Charcot Marie Tooth Disease (CMT), sponsored by Bopha Chrea. Recruiting at 1 site in United States. Open to participants aged 25 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Bopha Chrea · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
25 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Charcot-Marie-Tooth Disease with a site in United States — 9 open to participants now, 14 under way, 2 of them phase 3. Charcot-Marie-Tooth Disease · United States.

Planned enrollment
6th of 20
66 · median 30
Started
2025
with 3 others
No phase
7 of 41
1 open now
Primary completion
2026-08
later than 4 of 13 live
Registered
39th of 41
by date
Lead sponsor
1 of 41
Bopha Chrea

Among the 41 studies in Charcot-Marie-Tooth Disease with a site in United States, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 with no phase, reaches primary completion later than 4 of the 13 other live ones, and was the 39th registered.

Charcot-Marie-Tooth Disease

115 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 39 are open to participants now.

Browse Charcot-Marie-Tooth Disease studies →

Open to participants now

9 of the 41 studies in Charcot-Marie-Tooth Disease with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Charcot-Marie-Tooth Disease studies recruiting now, 14 (45%) set no upper age limit and 13 (42%) stop at 75 or younger; 14 take children under 18; 13 take healthy volunteers.

This study: 25 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Charcot-Marie-Tooth Disease with a site in United States, or all of them as a file.
02

Study summary

The overall objective of the proposed research is to begin to better understand the potential benefits and limitations of ankle -foot orthosis (AFO) use in the context of mobility and balance during gait for individuals with Charcot-Marie-Tooth disease (CMT). These benefits will be studied in comparison to those offered by surgical correction. We will accomplish by having subjects undergo mobility and balance tests in our gait analysis lab.

Read the detailed description

Walking is an important daily activity that is compromised in individuals with neuromuscular conditions. Charcot-Marie-Tooth (CMT) disease is the most common form of inherited peripheral neuropathy, affecting 2.8 million people worldwide and 1 in 2500 in the United States. Amongst patients with CMT, impaired walking is the most significant contributor to reduced quality of life in patients with CMT. Furthermore, these gait deficits result in over 80% of individuals with CMT experiencing a fall or near fall event annually, primarily due to tripping and balance related issues. Ankle foot orthoses (AFOs) are commonly used by individuals with CMT, often with the intent of reducing the risk of falls and restoring a more normal gait pattern. However, AFOs are often bulky, uncomfortable, and can be destabilizing for already weak individuals. Surgical correction offers the advantage of improving limb alignment, reduces bulk, and the arduous nature of donning/doffing a brace. However, surgery is not without risk, potential complications, and post-operative recovery. Scientific evidence to help surgeons determine if an AFO or surgery are optimal for a given patient, especially in the setting of a brace-able foot, remains limited. Recent consensus among expert orthopaedic foot and ankle surgeons agrees that 'There is no evidence-based orthopedic studies to help determine optimal timing for surgery, and there is often contradictory advice from the patient's neurologist, physical therapist, and orthotist regarding the role of an operation. There is a critical need to understand how surgical correction affects mobility, balance confidence, and gait compared to AFO bracing in the native cavovarus foot (non-operatively treated). Without such information, the evidence-based approach to answering this critical question will likely remain unrealized.

03

Conditions studied

  • Charcot Marie Tooth Disease (CMT)

Keywords

  • Gait Biomechanics
04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: 1) Clinical diagnosis and genetic confirmation of CMT, 2) Between the ages of 12 and 75, 3) Able to walk at a slow to moderate pace without an AFO, 3) Able to read and write in English and provide written . 4) Individuals in the NonOP group must have an AFO prescribed for daily activities. Individuals in the OP group will also have had 5) surgical correction of CMT cavovarus foot deformity focused on muscle balancing and hindfoot correction.

Exclusion Criteria: 1) Other causes or risk factors for peripheral neuropathy (for example diabetes, ETOH abuse), 2) Uncorrected visual impairment, 3) History of musculoskeletal injury requiring surgery 4) loss of plantar protective sensation 5) Pain >4/10 while walking (or an increase in pain during testing of >2/10), 6) Concern by the examiner that the individual will not complete the study. For the NonOP group 7) Previous surgical correction of CMT cavovarus foot deformity focused on muscle balancing and hindfoot correction

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • No intervention
    OP

    Charcot-Marie-Tooth patients who have undergone surgical correction but do not wear ankle-foot orthoses.

  • Other
    NonOP

    Charcot-Marie-Tooth patients who have not undergone surgical correction, but do wear clinically prescribed ankle-foot orthoses. NonOP subjects will complete study procedures both with and without their AFOs.

    Device: Ankle-foot Orthoses

Interventions

  • DeviceAnkle-foot Orthoses

    Group 1 will consist of individuals who have CMT and have undergone surgical correction (OP) and Group 2 will be AFO users who have CMT but have not undergone major surgical correction (NonOP).

06

What researchers measure

Primary outcomes

  1. Four-Square Step Test

    This test of functional mobility requires rapid stepping and changes in direction, that are often limited by lower limb pathology.

    Time frame: Baseline

  2. Self-selected Walking Velocity

    Participants will be instructed to walk at their "normal comfortable" pace for a 10 m distance. The time traveled between the 2 m mark and 8 m mark is recorded in seconds. Two trials will be completed with 15 seconds rest between trials.

    Time frame: Baseline

  3. Activity Specific Balance Confidence Scale

    The ABC is a well-established survey instrument to assess an individual participant's level of balance confidence during functional activities and takes approximately 3 minutes to complete.

    Time frame: Baseline

  4. Falls Frequency Questionnaire

    Survey asking participants the number of times they fell in the previous 24 hours and the previous week. Participants will also be asked to report the most circumstances most commonly associated with fall events.

    Time frame: Baseline

  5. Lower Extremity Gait Biomechanics

    Measurements include: toe clearance height and ankle dorsiflexion angle during swing, peak ankle plantar flexor moment, and peak ankle push off power.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • University of Iowa Medical Campus - North Liberty (MCNL)
    North Liberty, Iowa 52713, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.

Of 38 non-industry interventional studies with no phase under Charcot-Marie-Tooth Disease, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 67. This study's planned 12 months is below that.

Counting every sponsor, half of 38 studies reached it within 29 months; a quarter within 7 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 23, 2025
StartActual
Aug 14, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Jan 2027
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07188415
Lead sponsor
Bopha Chrea
Responsible party
Bopha Chrea (Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Sep 23, 2025
Start date
Aug 14, 2025
Primary completion
Aug 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Bopha Chrea, MD
Contact
bopha-chrea@uiowa.edu
319-356-3943
Lauren Crowe, BS
Contact
lauren-n-crowe@uiowa.edu
319-467-7128

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion